VIDEO: Study explores real-world treatment patterns of faricimab for wet AMD
In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Sophie J. Bakri, MD, discusses outcomes from the FARETINA-AMD study of faricimab as a treatment for age-related macular degeneration.
Data from the IRIS Registry was used to examine faricimab treatment patterns. Patients with a diagnosis of AMD, one or more faricimab injections from February 2022 to June of 2023, 6 months or more of follow-up and two or more best documented visual acuity measures on or after the first injection were included in the analysis. The researchers examined the interval extension of faricimab, defined as 6 weeks or greater between injections, Bakri explained.
“More than 50% of the eyes with wet AMD were able to achieve an extended faricimab interval of 6 weeks or greater within two initial injections of faricimab,” Bakri said.
Collapse
Bakri SJ. Real-world outcomes and treatment patterns with faricimab in AMD. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about